Puma Biotechnology Announces Initial Results From Phase 2 Trial For PB272

September 29, 2014 10:55 AM

15 0

(RTTNews.com) - Puma Biotechnology, Inc. ( PBYI ) Monday said efficacy results from a phase 2 clinical trial for lung cancer drug PB272 showed that, for the 13 patients who were on the drug alone and not in combination with temsirolimus, 7 achieved stable disease and 4 achieved clinical benefit.

PB272, or neratinib, is Puma's investigational drug for treating non-small cell lung cancer with HER2 mutations.

Read more

To category page